Speaker:

Without further ado, I'll introduce our first speaker for today,

Speaker:

Associate Professor Fred Joshua.

Speaker:

So he's a dedicated physician for the treatment of rheumatic diseases.

Speaker:

He has expertise in rheumatoid arthritis, ankylosing spondylitis,

Speaker:

and psoriatic arthritis, having completed a PhD in the use of ultrasound for

Speaker:

rheumatoid arthritis and presenting research internationally in these areas.

Speaker:

Associate Professor Joshua has pioneered Rheumatological ultrasound in Australia

Speaker:

And developed a degree for rheumatologists Through the Australian Society for

Speaker:

Ultrasound in Medicine Of which he is currently the President-elect,

Speaker:

Associate Professor Joshua has been involved In teaching med students and junior

Speaker:

doctors For many years, having previously been awarded The Prince of Wales Clinical

Speaker:

School Teacher of the Year Which is a fantastic achievement,

Speaker:

and he's now involved in developing undergrad medical programs at Macquarie

Speaker:

University where he is the Associate Professor of Medicine and the Rheumatology

Speaker:

Clinical Discipline Head. Fred, come up.

Speaker:

Thank you. Thank you very much for the opportunity and particularly to Jodie. She was fantastic.

Speaker:

I was perhaps not trying to be as helpful as I could have been in getting everything

Speaker:

set up and she really helped me to do this.

Speaker:

I have to echo the comments that were made about the orthopaedic group here. It's fantastic.

Speaker:

And not just the hospital, because I go up to level five quite a bit to the ward.

Speaker:

Clearly, I never go into the operating theater. You never want me in there.

Speaker:

But they do a fantastic job, particularly after the surgery as well.

Speaker:

So we have a great team of doctors in affiliated specialties to help if there are any issues.

Speaker:

So I've just found it fantastic actually working here because most of my work

Speaker:

had been in Ramwick and Cogger and I came here primarily for the university

Speaker:

and then being part of the hospital has just been fantastic really.

Speaker:

I am going to talk about now inflammatory diseases and how we can best assess them.

Speaker:

And I've got a couple of cases and I'll go through some of how we think about

Speaker:

it and how we can improve patient care through both recognition,

Speaker:

management of the drugs and assessment.

Speaker:

So I've been involved in clinical trials in the past as well as advisory groups

Speaker:

and medical education for pretty much everyone and I don't do as much now as

Speaker:

I'm primarily at the university but I have still done some medical education

Speaker:

primarily with them now.

Speaker:

So I've got two, this is the first case, and you'll recognize the first case

Speaker:

is similar to the second case, okay, and there'll be a few little differences.

Speaker:

So this is not an uncommon presentation. A 32-year-old young woman,

Speaker:

painful hands for about three months, swell across her right and left hand,

Speaker:

PIPs and MCPs, reducing her grip strength.

Speaker:

Notice she's been more tired. So fatigue and systemic upset is really how we

Speaker:

sort of differentiate these sort of problems.

Speaker:

So we think inflammatory disease, not just swelling, I also feel tired,

Speaker:

I feel a bit worn out, then considerable difficulty moving in the morning,

Speaker:

and our feet have been more painful in the morning for the last six months.

Speaker:

So often people will say, oh, I remember my feet were sore, but I changed shoes,

Speaker:

I did all of these things, and it seemed to keep on happening.

Speaker:

Then the swelling, but actually rheumatoid, in example, starts in the feet,

Speaker:

and then you get the grip strength problems. and then the fatigue is part of

Speaker:

that and an offer will proceed.

Speaker:

Otherwise, well, married, no kids. Yeah.

Speaker:

Okay. Oh, sorry. So you examine her.

Speaker:

General examination is sort of normal. Tenderness and swelling across the MCPs

Speaker:

and PIPs and MTPs. Got to take shoes off.

Speaker:

What do you think the diagnosis is and what differentials? Thoughts?

Speaker:

Good. So first up will be rheumatoid. What would be differentials?

Speaker:

Psoriatic arthritis. Anything else?

Speaker:

Lupus. And so these are the common things, right? So we would think rheumatoid one.

Speaker:

We will think possibly spondyloarthritis. And I want you to think of spondyloarthritis

Speaker:

rather than just psoriatic arthritis.

Speaker:

And then lupus. So these are our criteria.

Speaker:

So you're clearly well-versed. So this is how we think of it.

Speaker:

So rheumatoid criteria. And if you have a look, it's one joint with clinically

Speaker:

swollen or synovitis not better explained by another disease.

Speaker:

And the reason we have that is you can also use ultrasound or other imaging

Speaker:

techniques to prove that they have swollen joints.

Speaker:

So we don't always have to be able to see it.

Speaker:

Sometimes you can do another imaging technique. The imaging technique,

Speaker:

my PhD is about ultrasound which is a method of trying to determine whether

Speaker:

a joint's swollen or not, and an MRI can be done.

Speaker:

Now, when you do the ultrasound, you must specify that you're looking for inflammatory

Speaker:

arthritis because otherwise sometimes the radiologist won't be as well-versed.

Speaker:

Colin Chong, who works at Macquarie here, is really good at it.

Speaker:

He's pretty good at the imaging, so we ran a symposium with him.

Speaker:

Then serology, if you can prove rheumatoid factor or CCP antibody,

Speaker:

So rheumatoid factor will be positive in about 70% of patients.

Speaker:

CCP antibody also will be positive in around that level, but it's much more specific CCP antibody.

Speaker:

ESR and CRP, but have a look at this. This is important.

Speaker:

You don't have to have ESR and CRP being elevated to have rheumatoid arthritis.

Speaker:

You do not have to have ESR and CRP being elevated.

Speaker:

And then duration, early disease is six weeks.

Speaker:

That's what we call early disease now. Now, psoriatic arthritis,

Speaker:

and this is important in the classification, if you notice here in the story

Speaker:

here, you do not have to have psoriasis yourself anymore.

Speaker:

So the newer CASPAR criteria does not require you to have psoriasis yourself.

Speaker:

You can have a family history and then you can think, okay, maybe this person

Speaker:

has psoriatic arthritis based on that newer criteria.

Speaker:

And you can have more specific features for psoriatic arthritis,

Speaker:

which include dactylitis, sausage finger or toe, which does not happen so much in rheumatoid.

Speaker:

So you can say, I think psoriatic arthritis based on that.

Speaker:

And remember, the bigger group is spondyarthritis, back and joint diseases,

Speaker:

which we subdivide, psoriasis-related arthritis, ankylosing spondylitis,

Speaker:

reactive arthritis to an infection,

Speaker:

such as chlamydia or gastrointestinal illness, and then related to IBD.

Speaker:

So we've got that grouping, the subgroup is psoriatic arthritis.

Speaker:

Now lupus, before you could have ANA negative lupus, you can no longer have that.

Speaker:

By definition, you must have an ANA that's positive.

Speaker:

And the reason that was happening is because other diseases need to be thought of.

Speaker:

And there are newer ones such as IgG4 disease that may present like Sjogren's

Speaker:

or lupus, but it's actually a different condition.

Speaker:

So if the ANA is negative, by definition, they do not have lupus.

Speaker:

They may still have an inflammatory joint disease, but it cannot be lupus.

Speaker:

It might still be a connective tissue disease, so it could be something else in that pathway.

Speaker:

So you might have a different one.

Speaker:

Sjogren, sometimes the ANA is very rarely. Sometimes Sjogren is negative,

Speaker:

but you've got to think about other conditions is the key.

Speaker:

Okay, so in this scenario, we do blood testing and we come up with these tests.

Speaker:

ESR and CRP are elevated.

Speaker:

Rheumatoid factor, CCP, x-ray is nothing to see, which is extremely common.

Speaker:

You will not see anything on x-ray and this is a disincentive for people to get treatment.

Speaker:

So you've got to remember, please tell people just because your x-rays look

Speaker:

good, it's a window to the past.

Speaker:

X-rays are a window to the past.

Speaker:

Newer imaging, MR ultrasound is a window to the future, then what would you

Speaker:

do? What drugs do you reckon?

Speaker:

What would you do? Any ideas, guys?

Speaker:

Yeah, so you could do some anti-inflammatories DMARDS, the anti-inflammatories

Speaker:

for pain, the disease-modifying anti-rheumatic drugs to try and prevent future

Speaker:

harm, and sometimes we use prednisone.

Speaker:

People say, well, I hate prednisone. I don't like it either. But you've got to work.

Speaker:

You can't tell the rickshaw driver, go on a holiday. You're going to put food on the table, like me.

Speaker:

You're going to put food on the table, yeah? And so if you need food on the

Speaker:

table, you might take some prednisone in the short term to get through the problem.

Speaker:

So prednisone, why? Reduces pain, joint tenderness, improves grip strength,

Speaker:

better than anti-inflammatories.

Speaker:

It can reduce joint damage. It can.

Speaker:

So it's not like it's completely useless. It is actually a good drug.

Speaker:

You just can't keep doing it.

Speaker:

So once you've used it, do it. And when you're using it, I use 15. 1-5.

Speaker:

1-5. not 5-0. 5-0 is called the police, but in the American movies,

Speaker:

5-0 is that, but it's also asthma.

Speaker:

So don't use the asthma protocols. Use the rheumatological ones, 15.

Speaker:

Useful for flares. So you can say to people, use 15 for a couple of days,

Speaker:

then drop it quickly every three days and get rid of it.

Speaker:

You can use 50 if you have to, if it's really severe.

Speaker:

So chronic use, no good. Short-term, not really an issue. Longer-term,

Speaker:

all of those problems you already know.

Speaker:

So, you know, longer-term, you don't want to use it. So this is not telling anyone to anything.

Speaker:

You guys all know this. Weight gain, osteoporosis, diabetes, cataracts.

Speaker:

When you're using prednisone for a while, more than three months at greater

Speaker:

than 7.5 milligrams, that's when we start thinking about osteoporosis prophylaxis.

Speaker:

So she comes back. She says to you, thank you so much for the anti-inflammatories,

Speaker:

a short course of prednisone. I want to get onto disease-modifying drugs.

Speaker:

What pre-screening do you do to check before? Because you could do methotrexate

Speaker:

yourself if you wanted, if you feel comfortable.

Speaker:

Of course we're here to help. But if you wanted to, you could.

Speaker:

What would be the pre-screening and what medication would we choose?

Speaker:

And that depends a lot on what we're doing.

Speaker:

So pre-screening with hepatitis B, C serology and a chest x-ray.

Speaker:

The reason the chest x-ray is important is if they've got lung disease,

Speaker:

which some people will have, methotrexate can worsen that.

Speaker:

So it's well worth doing the chest x-ray as well.

Speaker:

Why do we do methotrexate? Reduces joint pain and swelling, reduces joint damage,

Speaker:

reduces disability. And this is the bit people forget to say,

Speaker:

you do not die as quickly.

Speaker:

You do not die as quickly from rheumatoid. Rheumatoid should not be called rheumatoid arthritis,

Speaker:

it should be called rheumatoid disease because it's a multi-system disease at

Speaker:

an increased rate of mortality, but we call it arthritis, which makes it seem less serious. Yeah.

Speaker:

If I said to you, you've got, and we know this with cancer.

Speaker:

If you say someone's got a skin cancer or a pre-cancer, you get more treatment.

Speaker:

The patient will beg you for more treatment.

Speaker:

If I say you've got a benign lesion in your skin that might be developing to

Speaker:

cancer one day, less treatment.

Speaker:

So this is a misnomer. You start with 10 milligrams of methotrexate,

Speaker:

increase each few weeks.

Speaker:

You can go by 5 milligrams or even 10.

Speaker:

Top dose, usually about 25. Folic acid, 10 milligrams, two tablets the next day.

Speaker:

Blood tests every month to three months.

Speaker:

What are you, this is a, you can use the Rheumatology Association leaflets to

Speaker:

give to a patient to say, what do you got for a rheumatoid?

Speaker:

What drugs can do? Go to the, there's a website there and this,

Speaker:

it's got all of our drugs.

Speaker:

You will know as much as me by the end of this, because you'll just know all

Speaker:

the websites, yeah, and you just go to the website.

Speaker:

Generally, I talk about, I tell people, I am not here to sell a drug.

Speaker:

Bug, I'm here to sell you a solution, but it's not perfect.

Speaker:

But if you do this, you will live longer. You will have less joint pain.

Speaker:

You will have less disability.

Speaker:

So it can cause hair loss. It can cause nausea. It can cause lymphopenia.

Speaker:

Liver function tests can occur.

Speaker:

Skin cancer risk, that's important.

Speaker:

The longer you're on it, the increased rate of skin cancer. So you've got to have screening.

Speaker:

Increase the folic acid if they get a bit of hair loss. You can also use minocyclin,

Speaker:

spironolactone, all of those other things for female pattern baldness.

Speaker:

Nausea usually gets better. Infections, you get an infection on methotrexate, stop the drug.

Speaker:

Yep. If on prednisone you continue, but if you get an infection,

Speaker:

stop methotrexate, restart once they're off antibiotics.

Speaker:

You cannot get pregnant on it and you cannot breastfeed on it. Yep.

Speaker:

You can father children on it.

Speaker:

You can father children on it. Just the women who can't have it.

Speaker:

Vaccinations. What do you do? Live vaccines? Out.

Speaker:

Can't use live vaccines. That's the list of the live vaccines.

Speaker:

Can have flu vax. Can have pneumonia vax. Can have shingrix. Should have shingrix.

Speaker:

COVID-19 can have. Yep. If you want to get the best response,

Speaker:

you miss the methotrexate for two weeks. Yep.

Speaker:

So if you miss the methotrexate for two weeks, then give the vaccine,

Speaker:

you get a better response.

Speaker:

But you might not do it because they're really suffering. Remember the rickshaw

Speaker:

driver. Got to work. Yep.

Speaker:

Yeah, they can. Because you might say, well, I want to reduce your problems

Speaker:

by using methotrexate, and your vaccine response might be slightly lower,

Speaker:

but that's better than nothing.

Speaker:

Otherwise, they flare, they hate the vaccination process. You make it easy.

Speaker:

Progress. She comes back, she says, it worked for a while.

Speaker:

The prednisone helped me with the flares. I want my disease under control because

Speaker:

I'm supposed to be perfect.

Speaker:

So more painful swollen joints, ESR and CRP rise, what's next? What do you think?

Speaker:

We've already got methotrexate on board. Anything else? We've got heaps of stuff.

Speaker:

We can move from methotrexate actually by a government.

Speaker:

I've simplified things a little bit. But actually by a government,

Speaker:

you've got to have a second drug for three months and then you can move to all

Speaker:

of these different biologics targeting different parts of the immune cascade.

Speaker:

We have TNF blockade, which we've got five different drugs.

Speaker:

We've got CTLA-4, agonist, avatacet. We've got CD20 drugs, which target B cells.

Speaker:

We have JAK inhibitors, which are not really a biologic.

Speaker:

The reason we call these things biologics is we, it's a very royal we,

Speaker:

it's not me, drug companies.

Speaker:

Drug company produces these anti-cytokine therapies by infecting a virus into

Speaker:

a bacteria that produces the antibody that we scoop up and inject.

Speaker:

And that's then a JAK inhibitor. Sorry, IL-6 and those.

Speaker:

JAK inhibitors are a targeted synthetic, so they're a tablet.

Speaker:

Targeted synthetic, so they're slightly different. But under government,

Speaker:

they fulfil the same sort of criteria to get them, but they are slightly different.

Speaker:

So you can see everyone should be fixed. We've got a heap of drugs.

Speaker:

This is where I was just going through the, oh, yeah.

Speaker:

Yeah.

Speaker:

Yes. Yes.

Speaker:

But you wouldn't do that. You would say, this is too difficult.

Speaker:

You would say, I'll send them along, because that's the complex person.

Speaker:

The person that doesn't have that, who is straightforward, that's what you would

Speaker:

do. The person that's more complicated, you say, that's the person that really

Speaker:

needs someone else to help to make sure.

Speaker:

It is brave, but you get proof.

Speaker:

Yeah, it is brave. But where would my truth come? I get an MRI,

Speaker:

show some swelling of joints, show joint destruction.

Speaker:

Go for it. But it's brave. You've got to do stuff. People are suffering.

Speaker:

So I get what you're saying. I don't like doing it, but I get some proof around it.

Speaker:

It's consultants' fees beyond their reach. That's a hard part.

Speaker:

That's the hospital part. I can't control that component.

Speaker:

But it is difficult. That part is really difficult. And so that is where we

Speaker:

need to have a health system that is better equipped. Yeah. Yeah.

Speaker:

This is more like a, thank you, this is more like a criteria because of the

Speaker:

PBS and money side. So if money was no object, Then, yeah. Would I go onto a

Speaker:

biologics straight away? It's always careful what you wish for.

Speaker:

Yeah, that's what I would like. Because sometimes these drugs can cause side effects too.

Speaker:

So, you know, we have experience of methotrexate for people on it for 50 years.

Speaker:

So it's a good drug. But if you get biologics faster, the chances of going into

Speaker:

a drug-free remission at two years is 50%.

Speaker:

But it means 50% at two years also relapse. So if we do it faster,

Speaker:

there's the possibility, there's even thoughts of using rituximab and changing

Speaker:

the course when people are pre-symptomatic.

Speaker:

So there is changing scale of this.

Speaker:

So it's possible as the drugs come down, we would use it faster.

Speaker:

And if people have ultimate money, sometimes we do it faster.

Speaker:

So we'll say, you know, you just pay for this and you can get it, but it's expensive.

Speaker:

So ideally, that would be the choice. Generally, yes. If you have biologic plus

Speaker:

drug faster, you do better. Thank you. Plus methotrexate.

Speaker:

These are the practicalities of it. Other immune disorders with TNF blockade

Speaker:

could occur. Like I could cause someone to get MS.

Speaker:

I could cause someone to get lupus.

Speaker:

It's great in pregnancy, however. It works in pregnancy.

Speaker:

It increases the risk of skin cancers. And it's coming down in price.

Speaker:

And you can switch medications and have effectiveness.

Speaker:

These are like most of these are subcut, so just do a little pen, pop it in.

Speaker:

These are the sort of common problems that you might face when people are on it.

Speaker:

Injection sites, this is what you do. Ask people to rotate the injection site.

Speaker:

Antihistamines may help. Cold packs can help. It does not relate to the drug working or not.

Speaker:

It's a short-lived histamine reaction but those histamine reactions can be quite

Speaker:

severe and we might have to change it but we just say, well,

Speaker:

that was not good for you next.

Speaker:

IL-6 blockade. So that was TNF blockade, right? So TNF blockade,

Speaker:

MS-like syndromes, lupus-like syndromes can occur.

Speaker:

Those are probably the biggest differentials. IL-6 blockade,

Speaker:

weekly subcadding injection.

Speaker:

It doesn't need methotrexate as much as TNF blockade does.

Speaker:

IL-6 blockade, the major risk is shingles, neutropenia, diverticulitis, cholesterol.

Speaker:

Remember, I'm not selling drug. I am selling solution.

Speaker:

And remember, people die from the problem. People get disability.

Speaker:

This stuff works, but it comes with risk. And we have to be ready for that.

Speaker:

Those are the common risks. Does it increase heart attacks with the increase

Speaker:

of hypercholesterolemia? No, it does not.

Speaker:

So it doesn't increase heart attacks. The cholesterol goes up,

Speaker:

but the heart attack rate does not. If you've got significant risk factors,

Speaker:

you do need to worry about it.

Speaker:

Oh, sorry That was me saying I should get a smiley face.

Speaker:

So CTLA-4, this is arentia or abatacep.

Speaker:

So this blocks co-stimulation of white cells to reduce rheumatoid.

Speaker:

It again, it can be used IV, it can be used subcut.

Speaker:

You have to use methotrexate with it. Without methotrexate, it's less effective.

Speaker:

It again increases skin cancers. All of these drugs, all immunosuppression increases skin cancers.

Speaker:

But it doesn't give you all those other issues I was telling you about. It's a pretty safe drug.

Speaker:

So it doesn't cause the TNF type problems. It doesn't cause the neutropenia. Pretty safe drug.

Speaker:

Rarely associated with, so if you look at rituximab, CD20, rarely associated

Speaker:

with like a multifocal leukoencopathy.

Speaker:

That's like mad cow disease.

Speaker:

Exceedingly rare. Really, really rare. We got bad problem.

Speaker:

This is useful, B cell depletion. Six monthly infusion.

Speaker:

So yes they've got problems yeah but

Speaker:

on average the problems are not so great

Speaker:

and do not occur especially if you're

Speaker:

young when you get older sure bad things

Speaker:

can happen but you stop it and if you stop the if you stop the illness early

Speaker:

you don't get all the other problems that used to happen okay jane says i've

Speaker:

responded well to tnf blockade and i gave a tnf blockade because Jane has not

Speaker:

had any children and she wants to have children.

Speaker:

She feels, is there longer term risks, however, of having rheumatoid? Oh, I keep doing that.

Speaker:

Oh, thank you. So, longer term, if your disease is active, you have less chance of falling pregnant.

Speaker:

Yeah? Important.

Speaker:

Pregnancy gets your arthritis better in 60% of people. Hypertension,

Speaker:

preeclampsia increased.

Speaker:

These are the people to contact to help with managing rheumatoid in pregnancy.

Speaker:

You can contact Deborah Kennedy, yeah, and she will help the patient feel comfortable about taking drugs.

Speaker:

These are some doctors in different areas of Sydney that help with obstetric medicine.

Speaker:

Yeah, like I just get everyone on board to help.

Speaker:

Yep, and you can look up on our Rheumatology Association what to tell people

Speaker:

in pregnancy. But basically, get disease under control, use TNF blockade.

Speaker:

Yep, that's basically it.

Speaker:

Osteoporosis rheumatoid increases osteoporosis disease itself but increased

Speaker:

medications especially prednisone increase the rate,

Speaker:

biologics is superior to conventional medicines for bone health they've got

Speaker:

to do strengthening and exercise that improves that have you heard of the Onero

Speaker:

program so the Onero program is the only physiotherapy program that has clear

Speaker:

proof of improving osteoporosis.

Speaker:

And you can look up different places. It's spelled O-N-E-R-O,

Speaker:

O-N-E-R-O Academy, and you can work out where those practitioners are.

Speaker:

But it's an accredited program.

Speaker:

This is important. Heart attacks and stroke are increased in people who have

Speaker:

inflammatory disease, particularly rheumatoid.

Speaker:

So people who have rheumatoid have more heart attacks. The more active your

Speaker:

disease, the more likely you are to have a heart attack from it.

Speaker:

Inflammatory disease increases cardiovascular mortality. So I send people for coronary screening.

Speaker:

I say, go see the cardiologist and get it sorted or speak to your GP and ask

Speaker:

them what we've got to do for cardiac screening.

Speaker:

Stress test alone is not good enough because a lot of people are fit.

Speaker:

So if you're fit and you go to a stress test, of course you pass.

Speaker:

It's a functional test. It doesn't tell us what your heart vessels are like.

Speaker:

It's additive to your traditional risk factors. So think of it as completely

Speaker:

separate, just like you'd think of smoking as completely separate.

Speaker:

Rheumatoid, risk factor of heart attacks and stroke.

Speaker:

Malignancy, it is increased in people with rheumatoid, not just from the drugs.

Speaker:

Everyone talks about the drugs, the drugs are going to give me cancer. No, it's the disease.

Speaker:

The disease increases the rate, especially lymphoma. But one of the things we

Speaker:

don't talk about is the lung cancer risk.

Speaker:

Lung cancer is increased in people with rheumatoid.

Speaker:

Got to check.

Speaker:

Yep, got to check. And the lung cancer screening protocols are in flux,

Speaker:

right? They're just changing now. Yep.

Speaker:

How long has it taken for the respiratory physicians and cardiothoracic surgeons

Speaker:

to go with the data? 15 years.

Speaker:

The data came out in 2010 for low-dose CT.

Speaker:

Yep, we've got to be ahead of that.

Speaker:

So non-melanoma skin cancers. So melanoma, we don't have proof,

Speaker:

but non-melanoma skin cancers.

Speaker:

Okay that's rheumatoid now janelle

Speaker:

so that was jane it's janelle bit of a play on

Speaker:

words but this is the same sort of story 32 year old lady painful hands for

Speaker:

three months the difference dip joints right fourth finger swollen reduced grip

Speaker:

strength more tired for six months that's systemic upset,

Speaker:

Difficulty moving in the morning Remembers her right ankle has been swollen

Speaker:

Otherwise well Married with no children Family history of psoriasis She does not have psoriasis.

Speaker:

You see how, you've got to ask. She's not going to come in and say,

Speaker:

yes, my father's got psoriasis. You've got to ask.

Speaker:

And then I look like a genius. Not really a genius, I'm just a hard worker.

Speaker:

Yeah, but I ask a lot, talk a lot. You can see I talk a lot.

Speaker:

When you do the tests, this time her inflammation markers are still elevated,

Speaker:

but the only difference is the rheumatoid factor and CCP are negative.

Speaker:

Same thing. Yeah. Yep. But when I showed you the story, they were asymmetric joints.

Speaker:

Yep. In the rheumatoid case, it was more symmetrical. This is asymmetric joints.

Speaker:

I think DIP involvement, that doesn't happen with rheumatoid.

Speaker:

One finger, that doesn't happen with rheumatoid. The ankle swelling,

Speaker:

why isn't it on the other side? Why isn't there some symmetry to this?

Speaker:

But the other features are the same. Systemic upset. I feel tired.

Speaker:

I feel worn out. I feel stiff.

Speaker:

Are there other problems with comorbidities? There absolutely is, and this is important.

Speaker:

Psoriasis is associated with all of these bits.

Speaker:

Joints, skin, spinal pain, so sacralitis or even fusion of spine, inflammation of eye,

Speaker:

tendonitis, which is really the join between tendon to bone,

Speaker:

inflamed to the point where you can get a hole in your heel.

Speaker:

Because the enthesis is eating away the bone.

Speaker:

Dactylitis, sausage toe, sausage finger, nail changes. I've got this fungal

Speaker:

infection that won't go.

Speaker:

It's not fungal, it's psoriasis.

Speaker:

IBD, or even just colitis indeterminate can occur.

Speaker:

This is what you've got to think of when someone presents with psoriasis.

Speaker:

But beyond that, look at this list. cholesterol,

Speaker:

blood pressure, depression diabetes,

Speaker:

obesity that is the metabolism and the mental health of someone with psoriasis

Speaker:

so when I think of people with psoriasis I think of psoriasis and inflammatory

Speaker:

disease in one component and all the different systems on the other component

Speaker:

I think of the metabolic consequences,

Speaker:

so I have dual goals Inflammatory disease, metabolic disease.

Speaker:

No point having great joints if you die. Yeah.

Speaker:

And they will die of the metabolic disease. That bit, you guys are fantastic at.

Speaker:

Fantastic. Yeah. But sometimes people don't think of it because they're thinking

Speaker:

of psoriasis as not a risk factor for heart attack and stroke.

Speaker:

Just like with rheumatoid, not thinking of it as a risk factor for heart attack and stroke.

Speaker:

Initial therapy, it's pretty similar. Use a bit of prednisone,

Speaker:

get people out of problems.

Speaker:

It doesn't work as well, and it's much more of an issue from the metabolic risk.

Speaker:

The weight gain in diabetes, more common. Yeah.

Speaker:

DMARTs, these are the ones we use. We talked about methotrexate already.

Speaker:

For government restrictions, you use leflunamide, which is very similar,

Speaker:

sulfasalazine. And then again, you go to biologics.

Speaker:

You can use 2 grams twice a day in combination with methotrexate if you need.

Speaker:

So she tried the methotrexate, didn't respond very well. She asks you,

Speaker:

is there any newer therapies? Yeah.

Speaker:

And you say, of course there is. Look at them all.

Speaker:

TNF blockade. IL-1223 blockade. IL-23 blockade.

Speaker:

IL-17 blockade. I made these slides one month ago.

Speaker:

In that one month, there's a new IL-23 blocking drug, Skyrizy.

Speaker:

JAK inhibitors, similar but different.

Speaker:

So TNF, JAK inhibitors were in the same, both in rheumatoid as well.

Speaker:

IL-12-23, IL-23 and IL-17 are specific for psoriasis and spondyloarthritis.

Speaker:

Yep, so there is differences. And that's because those drugs seem to work on the enthesis more.

Speaker:

Aisle 1223 and aisle 23, really safe.

Speaker:

They work well for skin, joints, enthesus, bowel, spine a little bit.

Speaker:

Very safe. The main problem is sinusitis.

Speaker:

Aisle 1223 requires you to draw it up, whereas the aisle 23s,

Speaker:

you just inject it again. Yep. Every two months.

Speaker:

Skyrizi, the newest one, is every three months.

Speaker:

Imagine that. Three months gets rid of your skin, joints, pain, feel better.

Speaker:

Three-monthly injection, and all you're going to get a risk of is sinusitis.

Speaker:

Realistically, it's just fantastic.

Speaker:

IL-17, fantastic for skin.

Speaker:

So if things are not working, skin disease, joints, and theses,

Speaker:

spine, main side effect is fungal infection. That's real.

Speaker:

Fungal infection is a problem. And it can make colitis unmask.

Speaker:

So you can get colitis. So you've got to be a bit careful. So you might do a

Speaker:

fecal calpropotectin before starting that.

Speaker:

JAK inhibitors. These are tablets. They are tofacidinib, baracidinib,

Speaker:

upadacidinib. Daily tablet.

Speaker:

The major risks are similar to IL-6, herpes, zosterone, neutropenia,

Speaker:

hypercholesterolemia.

Speaker:

But this is the big thing.

Speaker:

DVT pulmonary emboli are increased.

Speaker:

Cardiovascular diseases increase. Yeah.

Speaker:

So you've got to think about it. So I don't use them first line.

Speaker:

I would use the others first.

Speaker:

If you have, it's males and smokers that are the biggest risk for that,

Speaker:

for getting this problem.

Speaker:

But if you have uncontrolled disease, that's worse for your health from a cardiovascular

Speaker:

perspective than the drug.

Speaker:

She returns well and returns feeling when asked if there's any concern for the

Speaker:

future with psoriatic arthritis this time.

Speaker:

The comorbidities that we've touched upon, the metabolism, obesity,

Speaker:

diabetes, cholesterol, a zempic and, you know, wagovi, munjaro,

Speaker:

these are good for these people.

Speaker:

That's the way to fix this. Get rid of the obesity and diabetes and metabolism improves.

Speaker:

Takeaways, steroids, methotrexibologic, inflammatory arthritis is important

Speaker:

diagnostic considerations. to suggest what treatment will work.

Speaker:

Prednisone, conventional DMARDS can be used safely. So you guys could use those

Speaker:

drugs if you feel comfortable.

Speaker:

Don't do things you don't like. You know, if you don't like it, don't do it.

Speaker:

Do what you like to do. Get comfortable and then ask. We're here to help you.

Speaker:

I'm a bit busy, but of course I'll do my best.

Speaker:

There are multiple biologics that can help improve symptoms,

Speaker:

signs, and long-term harm from rheumatic disease.

Speaker:

Integrated care makes a difference. You, me, subspecialists.

Speaker:

Getting someone that can help

Speaker:

the skin, getting someone that can help the gut, it's cost prohibitive.

Speaker:

So we try and coordinate and I try and restrict how many times people come to see me.

Speaker:

But best health is costly. And so, you know, but if you do, and you can say,

Speaker:

okay, well, it's not as necessary because I've got this bit and it's all cost differential.

Speaker:

But you've got to talk about it, give people options. These are the things you can think about.

Speaker:

We have the hospitals, we have private health, we have all of these systems

Speaker:

to try and help. But we must talk about it and try and make things better.

Speaker:

Oh, this is my office. Don't worry about that so much. All right.

Speaker:

Thank you very much. I really appreciate the opportunity and the time. Thank you.